Thera-SAbDab

TOVETUMAB

>   Structural Summary
TherapeuticTovetumab
TargetPDGFRA
Heavy ChainQVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMNWIRQAPGKGLEWVSYISSSGSIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGRIAARGMDVWGQGTTVTVSS
Light ChainDIQMTQSPSSLSASVGDRVSITCRPSQSFSRYINWYQQKPGKAPKLLIHAASSLVGGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQTYSNPPITFGQGTRLEMK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2013
INN Year Recommended2014
Companies InvolvedCambridge Antibody Technology, MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedGlioblastoma, Non-small cell lung cancer, Solid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]